Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1802 Injection in Seasonal Allergic Rhinitis
CTR20253037Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of telikibart in seasonal allergic rhinitis (SAR), sponsored by Zhixiang Jintai. Started Aug 2025; status: completed.
02
Drugs
telikibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on CTR20253037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253037.